Chung, Man-Chin [UNESP]Silva, Antonio Távora de Albuquerque [UNESP]Castro, Lúcia Fioravanti [UNESP]Güido, Rafael Victório Carvalho [UNESP]Nassute, José Carlos [UNESP]Ferreira, Elizabeth Igne2014-05-202014-05-202005-06-01Revista Brasileira de Ciências Farmacêuticas. Divisão de Biblioteca e Documentação do Conjunto das Químicas da Universidade de São Paulo, v. 41, n. 2, p. 155-180, 2005.1516-9332http://hdl.handle.net/11449/8000O processo de modificação molecular denominado latenciação é revisto, apresentando formas avançadas no transporte de fármacos, utilizando macromoléculas como transportadores e sistemas de liberação sítio-específica como: CDS (Chemical Delivery System), ADEPT (Antibody-Directed Enzyme Prodrug Therapy), GDEPT/VDEPT (Gene-Directed Enzyme Prodrug Therapy/Vírus-Directed Enzyme Prodrug Therapy), ODDS (Osteotropic Drug Delivery System), PDEPT (Polymer-Directed Enzyme Prodrug Therapy), PELT (Polymer-Enzyme Liposome Therapy) e LEAPT (Lectin-Directed Enzyme-Activated Prodrug Therapy).This is a review about the molecular modification process, called latentiation, or prodrug design, focusing the progress in the prodrug approach using macromolecules as carriers and drug target systems as: PDEPT ( Polymer-Directed Enzyme Prodrug Therapy); PELT (Polymer-Enzyme Liposome Therapy); CDS (Chemical Delivery System); ADEPT(Antibody-Directed Enzyme Prodrug Therapy; GDEPT/VDEPT (Gene-Directed Enzyme Prodrug Therapy/Virus-Directed Enzyme Prodrug Therapy and ODDS (Osteotropic Drug Delivery System) and LEAPT (Lectin-Directed Enzyme-Activated Prodrug Therapy).155-180porLatenciaçãoPró-fármacosTransportadores macromolecularesSistemas de liberação específicaLatentiationProdrug designMacromolecular carriersDrug target systemsArtigo10.1590/S1516-93322005000200004S1516-93322005000200004Acesso aberto2-s2.0-26244457606S1516-93322005000200004.pdf97343336079754130000-0003-4141-0455